the cmdh started its activities in november 2005, replacing the informal mutual recognition facilitation group (mrfg), which was in operation over 10 years, to coordinate and facilitate the operation of the mutual recognition procedure. the cmdh is composed of one representative per member state and norway, iceland and liechtenstein, appointed for a renewable period of three years. the list of the cmdh members and alternates, their professional qualifications and declarations of interest are published on the cmdh and ema websites. observer status can be granted in line with the cmdh rules of procedure to other institutions (e.g. the chairperson of the cmdh is elected for a term of three years.
according to the rules of procedure, the cmdh has one elected vice-chairperson elected for a term of three years. the cmdh holds monthly meetings at the european medicines agency which usually have a duration of 3 days. the cmdh also publishes, on a yearly basis, a summary of the activities carried out by the cmdh and yearly statistics for new applications in the mutual recognition and decentralised procedures and for the applications referred to the cmdh. there is regular co-operation and exchanges of information on matters of mutual interest to both human and veterinary co-ordination groups, with regards to the mutual recognition and decentralised procedures. hma and cmdh/v are in the process of making appropriate changes to this website.
aesgp – variation classification of regular updates of smpc and pil as regards adverse effectsefpia – type ia variation label implementation guidanceega – presentationefpia – further use of srup (simplified repeat use procedure) in croatiaaesgp – q&a on api-mixtures. an unresolved regulatory problem request for marketing authorisation holders to assess the risk of occurrence of contamination with mesilate esters and related compounds in pharmaceuticals (this information should always be submitted with new applications). the united kingdom (uk) withdrew from the european union (eu) on 31 january 2020 and is no longer an eu member state. hma and cmdh/v are in the process of making appropriate changes to this website. if the site still contains content that does not yet reflect the withdrawal of the uk from the eu, this is unintentional and will be addressed. in case you notice information that should be updated, please report this website link using the contact form.
meeting 9-: agenda – minutes; meeting 12-: agenda – minutes 2012 – pharmacovigilance part of the cmdh minutes. meeting cmdh agendas and minutes 2021. meeting 14-: agenda – minutes; meeting 09-:agenda – minutes; meeting 12-14 october statistics agendas and minutes press releases covid-19 brexit procedural guidance cmdh-referrals product information advice from cmdh, prac meeting minutes, prac meeting minutes, cmdh press release, cmdh list of safety concerns, cmdh referral procedure.
new – 20-21 april cmdh minutes new – report from the meeting held on 22- new – minutes for november 2021 cmdh meeting with ips. the cmdh holds monthly meetings at the european medicines agency which usually have a duration of 3 days. the european medicines agency provides the secretariat cmdh press releases 2022 report from the meeting held on 8- update 05/01/2021; report from the meeting held on 10-, cmdh ema, prac recommendations, cmdh contact points, ema meeting today, cmdh variations, chmp, ad hoc cmdh meeting with interested parties on brexit monday 15 february 2021, cmdh dcp, cmdh members, prac agenda.
When you try to get related information on cmdh meeting minutes, you may look for related areas. prac meeting minutes, cmdh press release, cmdh list of safety concerns, cmdh referral procedure, cmdh ema, prac recommendations, cmdh contact points, ema meeting today, cmdh variations, chmp, ad hoc cmdh meeting with interested parties on brexit monday 15 february 2021, cmdh dcp, cmdh members, prac agenda.